CY1114777T1 - Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη - Google Patents
Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετηInfo
- Publication number
- CY1114777T1 CY1114777T1 CY20131101171T CY131101171T CY1114777T1 CY 1114777 T1 CY1114777 T1 CY 1114777T1 CY 20131101171 T CY20131101171 T CY 20131101171T CY 131101171 T CY131101171 T CY 131101171T CY 1114777 T1 CY1114777 T1 CY 1114777T1
- Authority
- CY
- Cyprus
- Prior art keywords
- single chain
- adenoviral
- compressors
- connector
- expressing interleukin
- Prior art date
Links
- 108010065805 Interleukin-12 Proteins 0.000 title abstract 5
- 102000013462 Interleukin-12 Human genes 0.000 title abstract 5
- 229940117681 interleukin-12 Drugs 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 102000002627 4-1BB Ligand Human genes 0.000 abstract 1
- 108010082808 4-1BB Ligand Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10248141A DE10248141B4 (de) | 2002-10-11 | 2002-10-11 | Nukleinsäuren und deren Verwendung für die Gentherapie |
| EP03757951.3A EP1556411B1 (de) | 2002-10-11 | 2003-10-10 | Adenovirale Vektoren die Einzelketten Interleukin-12 und 4-1BB Ligand exprimieren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114777T1 true CY1114777T1 (el) | 2016-12-14 |
Family
ID=32102775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101171T CY1114777T1 (el) | 2002-10-11 | 2013-12-27 | Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8067227B2 (https=) |
| EP (1) | EP1556411B1 (https=) |
| JP (2) | JP4615311B2 (https=) |
| AU (1) | AU2003273983A1 (https=) |
| CY (1) | CY1114777T1 (https=) |
| DE (1) | DE10248141B4 (https=) |
| DK (1) | DK1556411T3 (https=) |
| ES (1) | ES2440951T3 (https=) |
| PT (1) | PT1556411E (https=) |
| SI (1) | SI1556411T1 (https=) |
| WO (1) | WO2004035799A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069272A2 (en) * | 2003-02-05 | 2004-08-19 | Movecare Ltd | Adjuvant combination for use in the immunization of a mamal comprising il2 and il12 |
| DE102005055128B4 (de) * | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| CN102174479B (zh) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
| EP2766035B1 (en) | 2011-10-11 | 2018-03-28 | Universität Zürich Prorektorat MNW | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| EP3390643B8 (en) | 2015-12-18 | 2023-08-02 | OncoSec Medical Incorporated | Plasmid constructs for heterologous protein expression and methods of use |
| EP3211000B1 (en) | 2016-02-25 | 2019-01-30 | Provecs Medical GmbH | Novel immunostimulating vector system |
| SI3458083T1 (sl) | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba |
| TW202428301A (zh) | 2017-02-28 | 2024-07-16 | 法商賽諾菲公司 | 治療性rna |
| WO2018204528A1 (en) * | 2017-05-02 | 2018-11-08 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| BR112020014727A2 (pt) * | 2018-01-19 | 2020-12-08 | Kolon Life Science, Inc. | Vírus vaccinia recombinante e composição farmacêutica compreendendo o mesmo |
| JP7241161B2 (ja) | 2018-08-01 | 2023-03-16 | イミュニティーバイオ、インコーポレイテッド | 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム |
| US11230699B2 (en) * | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573764A (en) * | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
| AU3209300A (en) | 1999-01-15 | 2000-08-01 | Mount Sinai School Of Medicine Of The City University Of New York, The | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
| KR20020010206A (ko) * | 2000-07-27 | 2002-02-04 | 이시우 | 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신 |
| EP2336339A3 (en) * | 2000-09-25 | 2011-09-14 | The Regents of the University of Michigan | Production of viral vectors |
-
2002
- 2002-10-11 DE DE10248141A patent/DE10248141B4/de not_active Expired - Fee Related
-
2003
- 2003-10-10 SI SI200332329T patent/SI1556411T1/sl unknown
- 2003-10-10 AU AU2003273983A patent/AU2003273983A1/en not_active Abandoned
- 2003-10-10 EP EP03757951.3A patent/EP1556411B1/de not_active Expired - Lifetime
- 2003-10-10 US US10/530,706 patent/US8067227B2/en not_active Expired - Fee Related
- 2003-10-10 JP JP2004544141A patent/JP4615311B2/ja not_active Expired - Fee Related
- 2003-10-10 WO PCT/EP2003/011252 patent/WO2004035799A2/de not_active Ceased
- 2003-10-10 ES ES03757951.3T patent/ES2440951T3/es not_active Expired - Lifetime
- 2003-10-10 DK DK03757951.3T patent/DK1556411T3/da active
- 2003-10-10 PT PT37579513T patent/PT1556411E/pt unknown
-
2010
- 2010-08-30 JP JP2010192832A patent/JP2011036251A/ja active Pending
-
2013
- 2013-12-27 CY CY20131101171T patent/CY1114777T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011036251A (ja) | 2011-02-24 |
| AU2003273983A8 (en) | 2004-05-04 |
| AU2003273983A1 (en) | 2004-05-04 |
| EP1556411B1 (de) | 2013-10-02 |
| EP1556411A2 (de) | 2005-07-27 |
| US8067227B2 (en) | 2011-11-29 |
| ES2440951T3 (es) | 2014-01-31 |
| SI1556411T1 (sl) | 2014-01-31 |
| PT1556411E (pt) | 2014-01-07 |
| DE10248141B4 (de) | 2007-04-19 |
| JP4615311B2 (ja) | 2011-01-19 |
| DK1556411T3 (da) | 2014-01-20 |
| WO2004035799A3 (de) | 2004-06-10 |
| JP2006511212A (ja) | 2006-04-06 |
| WO2004035799A2 (de) | 2004-04-29 |
| DE10248141A1 (de) | 2004-09-02 |
| US20060153805A1 (en) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114777T1 (el) | Αδενοϊικοι κομιστες που εκφραζουν ιντερλευκινη-12 μονης αλυσιδας και 4-1ββ συνδετη | |
| FI961755A0 (fi) | Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi | |
| NO20004631D0 (no) | Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft | |
| AU2003242305A8 (en) | Hla-a24-restricted cancer antigen peptide | |
| DK1548032T3 (da) | KDR-peptider og vacciner indeholdende disse | |
| MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
| ATE375401T1 (de) | Vaccinia virus für diagnose und behandlung von tumoren | |
| CY1106783T1 (el) | Χρηση υλικου που περιεχει εικοσιδυ-πεντενοϊκο οξυ | |
| TW581808B (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| IL231502A0 (en) | Simian adenoid virus nucleic acid and amino acid sequences, vectors containing the same and methods of use | |
| DE69924826D1 (de) | Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie | |
| IL199126A (en) | Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters. | |
| FI961666A7 (fi) | Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria | |
| DK0637334T3 (da) | Peptider med en GDP-udskiftningsfaktoraktivitet, nukleinsyresekvenser, der koder for disse peptider, fremstilling og anvendelse | |
| DK1536006T3 (da) | Cancerantigener og anvendelse deraf | |
| DE60036105D1 (de) | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs | |
| DK1147212T3 (da) | T-hjælpecelle-epitoper | |
| DE69426121D1 (de) | Gen grb3-3, variante und ihre verwendungen | |
| DK0831899T3 (da) | Rekombinant koppevirus-calicivirus-præparater og anvendelser | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| DE602004001047D1 (de) | Phospholipidester von Clofarabin | |
| EP2149381A3 (en) | Method of treating malignancies through induction of blood immune responses | |
| DE69927214D1 (de) | Menschliches Gen und Protein eines Magenkrebs-Antigens | |
| ATE391777T1 (de) | Verwendung von prohibitin-rns in krebsbehandlung | |
| MXPA01011563A (es) | Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados. |